瑞香狠毒提取物尼地吗啉与长春新碱和阿霉素体外抗癌活性的比较  

A COMPARISON OF THE IN VITRO ANTITUMOR ACTIVITIES OF GNIDIMACRIN WITH VINCRISTIN (VCR) AND ADRIAMYCIN (ADM)

作　　者：冯威健[1] 吉田光二 池川哲郎 

机构地区：[1]河北医学院第四医院临床药物研究室,日本国立癌中心研究所

出　　处：《癌症》1994年第6期503-505,共3页Chinese Journal of Cancer

摘　　要：中药瑞香狼毒抗癌活性的主成分，二萜化合物尼地吗啉（ｇｎｉｄｉｍａｃｒｉｎ），在体外对小鼠白血病Ｌ─１２１０的细胞增殖及克隆形成均呈现浓度依赖性抑制作用，其５０％细胞增殖抑制浓度和５０％克隆形成抑制浓度（ＩＣ５０）较长春新碱低。对人白血病Ｋ５６２和胃癌Ｋａｔｏ─Ⅲ的５０％细胞增殖抑制浓度和５０％克隆形成抑制浓度（ＩＣ５０）均较阿霉素为低。Gnidimacrin, a diterpene compound, the main antitumor component ofStellera chamaejasme L.,showed dose-dependint response to inhibit mouse leukemia L-1210 in vitro.It showed lower IC50s of cell growth and colony forming than that of vin-cristine (VCR). Gnidimacrin also inhibits cell proliferation of human cancer cell lines suchas Leukemia K562 and gastric cancers Kato-Ⅲ in vitro. The IC50s of cell growth andcolony forming of gnidimacrin were lower than that of Adriamycin.

关 键 词：尼地吗啉 长春新碱 阿霉素 培养细胞 抗癌活性 

分 类 号：R730.5[医药卫生—肿瘤] R73－36[医药卫生—临床医学]